{
    "clinical_study": {
        "@rank": "115964", 
        "arm_group": [
            {
                "arm_group_label": "Systane Ultra", 
                "arm_group_type": "Experimental", 
                "description": "Systane Ultra lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II)."
            }, 
            {
                "arm_group_label": "Optive", 
                "arm_group_type": "Active Comparator", 
                "description": "Optive lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare Systane Ultra lubricant eye drops to Optive\n      lubricating eye drops for ocular surface staining within dry eye subjects and to evaluate\n      the safety of Systane Ultra after 3 months of use."
        }, 
        "brief_title": "Clinical Evaluation of Systane Ultra Compared to Optive in Ocular Surface Staining", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "detailed_description": {
            "textblock": "Following a 2-week washout phase with saline eye drops, subjects will be randomized to\n      receive either Systane Ultra or Optive for the remainder of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to attend all study visits.\n\n          -  Diagnosis of dry eye, as specified in protocol.\n\n          -  Uses artificial tears, as specified in protocol.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Poor visual acuity, as specified in protocol.\n\n          -  Women of childbearing potential who are pregnant, lactating, or not using adequate\n             birth control, as specified in protocol.\n\n          -  Any hypersensitivity or allergy to the investigational products or ingredients.\n\n          -  Any eye disorder, ocular surgery, medication, medical condition, or systemic disease,\n             as specified in protocol.\n\n          -  Contact lens use within 2 weeks of Screening Visit.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863368", 
            "org_study_id": "M-12-040"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Systane Ultra", 
                    "Optive"
                ], 
                "description": "1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.", 
                "intervention_name": "Preservative-free saline solution eyedrops", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Systane Ultra", 
                "intervention_name": "Systane Ultra lubricant eyedrops", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Optive", 
                "intervention_name": "Optive lubricating eyedrops", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrozoline"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dry eye syndrome", 
            "Systane Ultra", 
            "Optive", 
            "Ocular Surface Staining", 
            "OSDI", 
            "Eye drops"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Evaluation of Systane Ultra Compared to Optive in Ocular Surface Staining", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Steve Burmaster", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "France: National Consultative Ethics Committee for Health and Life Sciences", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The TOSS score is a cumulative cornea and conjunctival staining score. After instilling ophthalmic dye in the eye, the investigator grades three areas of the ocular surface for dryness on a scale from 0 to 5, where 0 is \"Absent\" and 5 is \"Severe.\" The three scores are summed for a resultant overall 0-15 score.", 
            "measure": "Change from baseline in Total Ocular Surface Staining (TOSS) Score at Day 35 (Phase I)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Day 35"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863368"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The OSDI is a 12-item, patient-reported outcome questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. Each item is scored on a 0-4 Likert-type scale, where 0 is \"None\" and 4 is \"All of the Time.\" A resultant overall 0-100 score is calculated, where 0 corresponds to no disability and 100 corresponds to complete disability.", 
                "measure": "Mean Ocular Surface Disease Index (OSDI) Score at Day 35 (Phase I)", 
                "safety_issue": "No", 
                "time_frame": "Day 35"
            }, 
            {
                "description": "The IDEEL is 10-question patient-reported outcome questionnaire that assesses the subject's general satisfaction with treatment use. A resultant overall 0-100 treatment satisfaction score is calculated, with higher scores indicating greater satisfaction and less treatment-related bother.", 
                "measure": "Mean Impact of Dry Eye on Everyday Life (IDEEL) treatment satisfaction score at Day 35 (Phase I)", 
                "safety_issue": "No", 
                "time_frame": "Day 35"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}